1-13 | The percentage of immunised children in Central African Republic (CAR) has fallen sharply since the crisis began in 2013. Médecins Sans Frontières (MSF) is now planning to vaccinate one quarter of all the country’s children against the principal childhood killer diseases. However, this type of campaign is exceptional due to the prohibitive cost of the pneumococcus vaccine. Médecins Sans Frontières (MSF) has launched a vaccination campaign of unprecedented scale targeting some 220,000 Central African children.
Syria: “Life in Raqqa was terrifying. During the day we lived with the government’s airstrikes; at night there were coalition airstrikes”
12-15 | Dr. Marwan* worked with MSF in Tal Abyad, northern Syria. After refusing a job offer from Islamic State of Iraq and Syria (ISIS) militants, he knew his life was in danger, and made the hard decision to leave for Europe. “I was a paediatric doctor in Syria, married with two children. We lived in Raqqa, now known as the stronghold of the Islamic State of Iraq and Syria (ISIS).
11-12 | MSF Asks Supporters in Southeast Asia to TURN RED for more affordable pneumonia vaccine Hong Kong/Jakarta, 12 November 2015—The international medical humanitarian organisation Médecins Sans Frontières/Doctors Without Borders (MSF) launched ‘A Fair Shot’ online campaign today on World Pneumonia Day.
7-28 | The clock is ticking. Asian countries are under time pressure to sacrifice public health interests to get final agreement on a trade deal. The Trans-Pacific Partnership (TPP), which is currently being negotiated between the US and 11 other Pacific Rim nations – including Malaysia, Singapore, Brunei, Japan and Vietnam – is on track to become the most harmful trade pact ever for access to low-cost medicines in developing countries. Last month, the U.S.
6-19 | Médecins Sans Frontières (MSF) response to the news MSF has learned that the Chinese patent office has just denied Gilead Science’s request for a key patent on the hepatitis C drug sofosbuvir. This drug, together with other antivirals, is the backbone of several newer, more effective curative treatment for hepatitis C, yet is exorbitantly priced in many countries, restricting access for people who need it.